Trending Now - Eli Lilly Revives Vaccine Efforts With $4 Billion Investment
WHO:
Bloomberg - Eli Lilly & Co. is acquiring three clinical-stage vaccine developers.
CNBC - Daniel M. Skovronsky is the chief scientific and product officer and president of Eli Lilly.
WHAT:
CNBC - Eli Lilly's acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences, according to Daniel M. Skovronsky.
CNBC - LimmaTech aims to tackle bacterial pathogens, including sexually transmitted infections like Neisseria gonorrhoeae and chlamydia trachomatis.
CNBC - The Vaccine Company is developing In Vivo Nanoparticle (IVN) technologies to safely deliver drugs, genetic material, or diagnostic sensors into the living body and combat viral pathogens, including the Epstein-Barr Virus.
Bloomberg - Eli Lilly is buying three clinical-stage vaccine developers for as much as $3.8 billion.
CNBC - Eli Lilly announced plans to acquire Curevo for $1.5 billion, LimmaTech Biologics for $780 million, and Vaccine Company for $1.55 billion.
CNBC - Eli Lilly's shares rose 1.3% in premarket trading following the announcement.
CNBC - Eli Lilly's first-quarter revenue in the U.S. for Zepbound was $4.16 billion and for Mounjaro was $4.2 billion.
WHERE:
CNBC - The acquisitions are part of Eli Lilly's strategy to expand into infectious diseases.
WHEN:
CNBC - Eli Lilly plans to roll out its newly approved GLP-1 obesity pill Foundayo in the second quarter.
WHY:
CNBC - Eli Lilly's acquisitions reflect a strategy to prevent disease at its source rather than treat its consequences.
CNBC - LimmaTech aims to tackle bacterial pathogens where there's increased antimicrobial drug resistance.
HOW:
CNBC - Curevo has developed a vaccine for the prevention of shingles in adults, specifically engineered with a synthetic adjuvant to increase immune system tolerability and reduce side effects.
CNBC - Curevo has developed a vaccine for shingles using a synthetic adjuvant to increase immune system tolerability and reduce side effects.
CNBC - The Vaccine Company is developing In Vivo Nanoparticle (IVN) technologies to deliver drugs and combat viral pathogens.
(UPDATED May 26, 2026 17:56 UTC)
Eli Lilly is pursuing a strategic approach focused on preventing diseases at their source, as highlighted by Daniel M. Skovronsky. LimmaTech is working to address bacterial pathogens, including sexually transmitted infections like Neisseria gonorrhoeae and chlamydia trachomatis, while The Vaccine Company is developing In Vivo Nanoparticle technologies to deliver treatments safely and combat viral pathogens such as the Epstein-Barr Virus. Additionally, Curevo has created a shingles vaccine for adults that uses a synthetic adjuvant to enhance immune system tolerability and minimize side effects.
--
(UPDATED May 26, 2026 16:19 UTC)
Eli Lilly is making a significant move in the healthcare sector by acquiring three clinical-stage vaccine developers for as much as $3.8 billion, including Curevo for $1.5 billion, LimmaTech Biologics for $780 million, and Vaccine Company for $1.55 billion. This strategy aims to expand Eli Lilly's focus on infectious diseases and reflects a commitment to preventing illness at its source, with LimmaTech specifically targeting bacterial pathogens amid rising antimicrobial resistance. Following the announcement, Eli Lilly's shares rose 1.3% in premarket trading, and the company plans to roll out its newly approved GLP-1 obesity pill, Foundayo, in the second quarter.